Clinical remission of mild-to-moderate asthma: Rates, contributing factors, and stability
Background: Although clinical remission (CR) of severe asthma has been extensively investigated, CR of mild-to-moderate asthma remains unexplored. Objective: This study aimed to determine CR rates, contributing factors, and stability in patients with mild-to-moderate asthma. Methods: We retrospectiv...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Journal of Allergy and Clinical Immunology: Global |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772829325000323 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849323355548680192 |
|---|---|
| author | Mana Ishizuka, MD Naoya Sugimoto, MD, PhD Konomi Kobayashi, MD Yuri Takeshita, MD, PhD Sahoko Imoto, MD, PhD Yuta Koizumi, MD, PhD Yusuke Togashi, MD Yutaro Tanaka, MD Maki Nagata, MD Saya Hattori, MD Yuki Uehara, MD Yuki Suzuki, MD, PhD Hikaru Toyota, MD, PhD Satoru Ishii, MD, PhD Hiroyuki Nagase, MD, PhD |
| author_facet | Mana Ishizuka, MD Naoya Sugimoto, MD, PhD Konomi Kobayashi, MD Yuri Takeshita, MD, PhD Sahoko Imoto, MD, PhD Yuta Koizumi, MD, PhD Yusuke Togashi, MD Yutaro Tanaka, MD Maki Nagata, MD Saya Hattori, MD Yuki Uehara, MD Yuki Suzuki, MD, PhD Hikaru Toyota, MD, PhD Satoru Ishii, MD, PhD Hiroyuki Nagase, MD, PhD |
| author_sort | Mana Ishizuka, MD |
| collection | DOAJ |
| description | Background: Although clinical remission (CR) of severe asthma has been extensively investigated, CR of mild-to-moderate asthma remains unexplored. Objective: This study aimed to determine CR rates, contributing factors, and stability in patients with mild-to-moderate asthma. Methods: We retrospectively analyzed 263 patients with asthma. Three-component CR was defined as no exacerbation, no daily oral corticosteroid receipt, and an Asthma Control Test score equivalent to that of the well control; 4-component CR included these parameters plus forced expiratory volume in 1 second of ≥80% predicted. CR during the 1 year and stability of CR over 10 years were retrospectively analyzed in patients with mild-to-moderate and severe asthma. Results: The CR rates were significantly higher (4-component, 73.2%; 3-component, 81.0%) in patients with mild-to-moderate asthma compared with the CR rate in patients with severe asthma (4-component, 33.9%; and 3-component, 30.6%). A lower smoking index contributed to 3- and 4-component CR. Lower body mass index contributed to 3-component remission, and later onset and shorter asthma duration contributed to 4-component remission. In patients experiencing 4-component remission 10 years before, 80.3% maintained disease in remission; 89.1% of patients experiencing 3-component remission maintained disease in remission. In patients with disease that did not maintain 4-component CR after 10 years, predicted forced expiratory volume decreased, but no differences in inhaled corticosteroid and long-acting β-agonists/long-acting muscarinic antagonists receipt were detected between 10 years ago and the present. The current muscarinic antagonist receipt remained low, at 16.7%. Conclusion: CR, including normalized forced expiratory volume, is obtainable and sustainable in most Japanese patients with mild-to-moderate asthma. Assessing CR in these patients may help avoid undertreatment and reduce future risks. |
| format | Article |
| id | doaj-art-ea420326e75a47a19dbda060a17cec21 |
| institution | Kabale University |
| issn | 2772-8293 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Allergy and Clinical Immunology: Global |
| spelling | doaj-art-ea420326e75a47a19dbda060a17cec212025-08-20T03:49:03ZengElsevierJournal of Allergy and Clinical Immunology: Global2772-82932025-05-014210043110.1016/j.jacig.2025.100431Clinical remission of mild-to-moderate asthma: Rates, contributing factors, and stabilityMana Ishizuka, MD0Naoya Sugimoto, MD, PhD1Konomi Kobayashi, MD2Yuri Takeshita, MD, PhD3Sahoko Imoto, MD, PhD4Yuta Koizumi, MD, PhD5Yusuke Togashi, MD6Yutaro Tanaka, MD7Maki Nagata, MD8Saya Hattori, MD9Yuki Uehara, MD10Yuki Suzuki, MD, PhD11Hikaru Toyota, MD, PhD12Satoru Ishii, MD, PhD13Hiroyuki Nagase, MD, PhD14Department of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Tokyo, JapanCorresponding author: Naoya Sugimoto, MD, PhD, 173-8605, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo, Japan.; Department of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Tokyo, JapanDepartment of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Tokyo, JapanDepartment of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Tokyo, JapanDepartment of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Tokyo, JapanDepartment of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Tokyo, JapanDepartment of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Tokyo, JapanDepartment of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Tokyo, JapanDepartment of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Tokyo, JapanDepartment of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Tokyo, JapanDepartment of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Tokyo, JapanDepartment of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Tokyo, JapanDepartment of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Tokyo, JapanDepartment of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Tokyo, JapanDepartment of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, Tokyo, JapanBackground: Although clinical remission (CR) of severe asthma has been extensively investigated, CR of mild-to-moderate asthma remains unexplored. Objective: This study aimed to determine CR rates, contributing factors, and stability in patients with mild-to-moderate asthma. Methods: We retrospectively analyzed 263 patients with asthma. Three-component CR was defined as no exacerbation, no daily oral corticosteroid receipt, and an Asthma Control Test score equivalent to that of the well control; 4-component CR included these parameters plus forced expiratory volume in 1 second of ≥80% predicted. CR during the 1 year and stability of CR over 10 years were retrospectively analyzed in patients with mild-to-moderate and severe asthma. Results: The CR rates were significantly higher (4-component, 73.2%; 3-component, 81.0%) in patients with mild-to-moderate asthma compared with the CR rate in patients with severe asthma (4-component, 33.9%; and 3-component, 30.6%). A lower smoking index contributed to 3- and 4-component CR. Lower body mass index contributed to 3-component remission, and later onset and shorter asthma duration contributed to 4-component remission. In patients experiencing 4-component remission 10 years before, 80.3% maintained disease in remission; 89.1% of patients experiencing 3-component remission maintained disease in remission. In patients with disease that did not maintain 4-component CR after 10 years, predicted forced expiratory volume decreased, but no differences in inhaled corticosteroid and long-acting β-agonists/long-acting muscarinic antagonists receipt were detected between 10 years ago and the present. The current muscarinic antagonist receipt remained low, at 16.7%. Conclusion: CR, including normalized forced expiratory volume, is obtainable and sustainable in most Japanese patients with mild-to-moderate asthma. Assessing CR in these patients may help avoid undertreatment and reduce future risks.http://www.sciencedirect.com/science/article/pii/S2772829325000323Clinical remissionmild asthmamoderate asthmastabilitypractical guidelines for asthma managementpulmonary function |
| spellingShingle | Mana Ishizuka, MD Naoya Sugimoto, MD, PhD Konomi Kobayashi, MD Yuri Takeshita, MD, PhD Sahoko Imoto, MD, PhD Yuta Koizumi, MD, PhD Yusuke Togashi, MD Yutaro Tanaka, MD Maki Nagata, MD Saya Hattori, MD Yuki Uehara, MD Yuki Suzuki, MD, PhD Hikaru Toyota, MD, PhD Satoru Ishii, MD, PhD Hiroyuki Nagase, MD, PhD Clinical remission of mild-to-moderate asthma: Rates, contributing factors, and stability Journal of Allergy and Clinical Immunology: Global Clinical remission mild asthma moderate asthma stability practical guidelines for asthma management pulmonary function |
| title | Clinical remission of mild-to-moderate asthma: Rates, contributing factors, and stability |
| title_full | Clinical remission of mild-to-moderate asthma: Rates, contributing factors, and stability |
| title_fullStr | Clinical remission of mild-to-moderate asthma: Rates, contributing factors, and stability |
| title_full_unstemmed | Clinical remission of mild-to-moderate asthma: Rates, contributing factors, and stability |
| title_short | Clinical remission of mild-to-moderate asthma: Rates, contributing factors, and stability |
| title_sort | clinical remission of mild to moderate asthma rates contributing factors and stability |
| topic | Clinical remission mild asthma moderate asthma stability practical guidelines for asthma management pulmonary function |
| url | http://www.sciencedirect.com/science/article/pii/S2772829325000323 |
| work_keys_str_mv | AT manaishizukamd clinicalremissionofmildtomoderateasthmaratescontributingfactorsandstability AT naoyasugimotomdphd clinicalremissionofmildtomoderateasthmaratescontributingfactorsandstability AT konomikobayashimd clinicalremissionofmildtomoderateasthmaratescontributingfactorsandstability AT yuritakeshitamdphd clinicalremissionofmildtomoderateasthmaratescontributingfactorsandstability AT sahokoimotomdphd clinicalremissionofmildtomoderateasthmaratescontributingfactorsandstability AT yutakoizumimdphd clinicalremissionofmildtomoderateasthmaratescontributingfactorsandstability AT yusuketogashimd clinicalremissionofmildtomoderateasthmaratescontributingfactorsandstability AT yutarotanakamd clinicalremissionofmildtomoderateasthmaratescontributingfactorsandstability AT makinagatamd clinicalremissionofmildtomoderateasthmaratescontributingfactorsandstability AT sayahattorimd clinicalremissionofmildtomoderateasthmaratescontributingfactorsandstability AT yukiueharamd clinicalremissionofmildtomoderateasthmaratescontributingfactorsandstability AT yukisuzukimdphd clinicalremissionofmildtomoderateasthmaratescontributingfactorsandstability AT hikarutoyotamdphd clinicalremissionofmildtomoderateasthmaratescontributingfactorsandstability AT satoruishiimdphd clinicalremissionofmildtomoderateasthmaratescontributingfactorsandstability AT hiroyukinagasemdphd clinicalremissionofmildtomoderateasthmaratescontributingfactorsandstability |